The role of tenofovir alafenamide in future HIV management.

Abstract:

:HIV infection has become a chronic condition rather than an acute life-threatening disease in developed countries, thanks to consistent innovation and evolution of effective interventions. This has altered HIV management and created new challenges. People living with HIV (PLWHIV) are living longer and so encounter comorbidities linked not only with their disease, but also with ageing, lifestyle and chronic exposure to antiretroviral therapy (ART). Although longevity, viral suppression and the prevention of viral transmission remain key goals, more needs to be achieved to encompass the vision of attaining an optimum level of overall health. Treatment choices and management practices should ensure patients' long-term health with minimal comorbidity. Treatments that balance optimal efficacy with the potential for improved long-term safety are needed for all patients. In this review, we consider the evolution and development of tenofovir alafenamide (TAF), a novel prodrug of tenofovir which offers high antiviral efficacy at doses over ten times lower than that of tenofovir disoproxil fumarate (TDF). Emerging clinical data suggest that elvitegravir, cobicistat, emtricitabine and TAF (E/C/F/TAF) as a single-tablet regimen offers highly effective viral suppression in treatment-naïve and treatment-experienced patients with an improved renal and bone safety profile compared with TDF, this having been demonstrated in diverse groups including patients with existing renal impairment and adolescents. The profile of TAF identifies it as an agent with a promising role within future ART regimens that aim to deliver the vision of undetectable viral load, while requiring less monitoring and having a safety profile designed to minimize comorbid risks while supporting good long-term health.

journal_name

HIV Med

journal_title

HIV medicine

authors

Antela A,Aguiar C,Compston J,Hendry BM,Boffito M,Mallon P,Pourcher-Martinez V,Di Perri G

doi

10.1111/hiv.12401

subject

Has Abstract

pub_date

2016-05-01 00:00:00

pages

4-16

eissn

1464-2662

issn

1468-1293

journal_volume

17 Suppl 2

pub_type

杂志文章,评审
  • A randomized study investigating the efficacy and safety of amprenavir in combination with low-dose ritonavir in protease inhibitor-experienced HIV-infected adults.

    abstract:OBJECTIVES:To compare the safety and efficacy of amprenavir [APV/j Agenerase trade mark; GlaxoSmithKline, [Ware, UK; 600 mg twice a day (bid)] boosted with low-dose ritonavir (RTV, 100 mg bid) with those of other protease inhibitors (PIs) in PI-experienced HIV-infected patients. STUDY DESIGN:Parallel-group, randomized...

    journal_title:HIV medicine

    pub_type: 临床试验,杂志文章,多中心研究,随机对照试验

    doi:10.1111/j.1468-1293.2004.00224.x

    authors: Pulido F,Katlama C,Marquez M,Thomas R,Clumeck N,Pedro Rde J,Cattelan AM,Zhu C,Tymkewycz P

    更新日期:2004-07-01 00:00:00

  • Coronavirus disease 2019 (COVID-19) outcomes in HIV/AIDS patients: a systematic review.

    abstract:OBJECTIVES:The aim of the study was to systematically review current studies reporting on clinical outcomes in people living with HIV (PLHIV) infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). METHODS:We conducted a systematic review using the Preferred Reporting Items for Systematic Reviews a...

    journal_title:HIV medicine

    pub_type: 杂志文章

    doi:10.1111/hiv.12911

    authors: Cooper TJ,Woodward BL,Alom S,Harky A

    更新日期:2020-10-01 00:00:00

  • Hepatitis C in men who have sex with men in London--a community survey.

    abstract:OBJECTIVES:For the last 10 years there has been an epidemic of hepatitis C virus (HCV) infection in men who have sex with men (MSM) in Europe, North America and Australia. The majority of those infected are also HIV-positive and it is unclear to what extent HIV-negative MSM are also at increased risk of infection with ...

    journal_title:HIV medicine

    pub_type: 杂志文章

    doi:10.1111/hiv.12050

    authors: Price H,Gilson R,Mercey D,Copas A,Parry J,Nardone A,Johnson A,Hart G

    更新日期:2013-10-01 00:00:00

  • Polypharmacy and potential drug-drug interactions for people with HIV in the UK from the Climate-HIV database.

    abstract:OBJECTIVES:People with HIV (PWHIV) are likely to need therapies for comorbidities as they age. We assessed risk of drug-drug interactions (DDIs) in PWHIV. METHODS:The Climate-HIV electronic recording system was used to cross-sectionally analyse records from PWHIV aged ≥ 18 years attending four UK HIV units with a curr...

    journal_title:HIV medicine

    pub_type: 杂志文章

    doi:10.1111/hiv.12879

    authors: Okoli C,Schwenk A,Radford M,Myland M,Taylor S,Darley A,Barnes J,Fox A,Grimson F,Reeves I,Munshi S,Croucher A,Boxall N,Benn P,Paice A,van Wyk J,Khoo S

    更新日期:2020-09-01 00:00:00

  • Nevirapine- versus efavirenz-based highly active antiretroviral therapy regimens in antiretroviral-naïve patients with advanced HIV infection.

    abstract:OBJECTIVE:To compare virological and immunological responses to nevirapine (NVP)-based and efavirenz (EFV)-based highly active antiretroviral therapy (HAART) regimens in antiretroviral-naïve patients with advanced HIV infection. METHODS:A retrospective observational cohort study was conducted on antiretroviral-naïve H...

    journal_title:HIV medicine

    pub_type: 杂志文章

    doi:10.1111/j.1468-1293.2004.00195.x

    authors: Manosuthi W,Sungkanuparph S,Vibhagool A,Rattanasiri S,Thakkinstian A

    更新日期:2004-03-01 00:00:00

  • Quantifying the drivers of HIV transmission and prevention in men who have sex with men: a population model-based analysis in Switzerland.

    abstract:OBJECTIVES:Despite the huge success of antiretroviral therapy (ART), there is an ongoing HIV epidemic among men who have sex with men (MSM) in resource-rich countries. Understanding the driving factors underlying this process is important for curbing the epidemic. METHODS:We simulated the HIV epidemic in MSM in Switze...

    journal_title:HIV medicine

    pub_type: 杂志文章

    doi:10.1111/hiv.12660

    authors: Kusejko K,Marzel A,Hampel B,Bachmann N,Nguyen H,Fehr J,Braun DL,Battegay M,Bernasconi E,Calmy A,Cavassini M,Hoffmann M,Böni J,Yerly S,Klimkait T,Perreau M,Rauch A,Günthard HF,Kouyos RD,Swiss HIV Cohort Study.

    更新日期:2018-11-01 00:00:00

  • Paediatric antiretroviral therapy audit in South London.

    abstract:OBJECTIVES:To audit clinical and surrogate marker outcome data following the introduction of combination antiretroviral therapy to HIV-infected children in South London. METHODS:We performed a retrospective cohort study of 110 HIV-infected children under the care of the Paediatric HIV in South London Network (PHILS-NE...

    journal_title:HIV medicine

    pub_type: 杂志文章

    doi:10.1046/j.1464-2662.2001.00098.x

    authors: Doerholt K,Sharland M,Ball C,DuMont G

    更新日期:2002-01-01 00:00:00

  • An oral formulation of efavirenz-loaded lactoferrin nanoparticles with improved biodistribution and pharmacokinetic profile.

    abstract:OBJECTIVES:Efavirenz (EFV), a non-nucleoside reverse transcriptase inhibitor, is a drug that is frequently included in highly active antiretroviral therapy for treatment of HIV infection. Decreased bioavailability and increased toxicity limit its use. We report a formulation of efavirenz-loaded lactoferrin nanoparticle...

    journal_title:HIV medicine

    pub_type: 杂志文章

    doi:10.1111/hiv.12475

    authors: Kumar P,Lakshmi YS,Kondapi AK

    更新日期:2017-08-01 00:00:00

  • Attitudes towards new HIV biomedical prevention technologies among a cohort of HIV-negative gay men in Sydney, Australia.

    abstract:OBJECTIVES:The aim of the study was to explore the awareness of rectal microbicides, the use of pre-exposure prophylaxis (PREP) and the willingness to participate in biomedical HIV prevention trials in a cohort of HIV-negative gay men. METHODS:In a community-based cohort study, HIV-negative homosexually active men in ...

    journal_title:HIV medicine

    pub_type: 杂志文章

    doi:10.1111/j.1468-1293.2009.00777.x

    authors: Poynten IM,Jin F,Prestage GP,Kaldor JM,Imrie J,Grulich AE

    更新日期:2010-04-01 00:00:00

  • Virological failure and HIV drug resistance among adults living with HIV on second-line antiretroviral therapy in the Asia-Pacific.

    abstract:OBJECTIVES:To assess second-line antiretroviral therapy (ART) virological failure and HIV drug resistance-associated mutations (RAMs), in support of third-line regimen planning in Asia. METHODS:Adults > 18 years of age on second-line ART for ≥ 6 months were eligible. Cross-sectional data on HIV viral load (VL) and gen...

    journal_title:HIV medicine

    pub_type: 杂志文章

    doi:10.1111/hiv.13006

    authors: Ross J,Jiamsakul A,Kumarasamy N,Azwa I,Merati TP,Do CD,Lee MP,Ly PS,Yunihastuti E,Nguyen KV,Ditangco R,Ng OT,Choi JY,Oka S,Sohn AH,Law M

    更新日期:2020-11-05 00:00:00

  • HIV prevalence and HIV clinical outcomes of transgender and gender-diverse people in England.

    abstract:OBJECTIVES:We provide the first estimate of HIV prevalence among trans and gender-diverse people living in England and compare outcomes of people living with HIV according to gender identity. METHODS:We analysed a comprehensive national HIV cohort and a nationally representative self-reported survey of people accessin...

    journal_title:HIV medicine

    pub_type: 杂志文章

    doi:10.1111/hiv.12987

    authors: Kirwan PD,Hibbert M,Kall M,Nambiar K,Ross M,Croxford S,Nash S,Webb L,Wolton A,Delpech VC

    更新日期:2021-02-01 00:00:00

  • Utilization of absolute monocyte counts to predict cardiovascular events in people living with HIV.

    abstract:OBJECTIVES:Cardiovascular risk is increased in people living with HIV (PLWH). In HIV-uninfected populations, total absolute monocyte count (AMC) has been shown to be predictive of future cardiovascular events (CVEs). We sought to determine whether AMC predicts CVEs in PLWH independent of established and HIV-related car...

    journal_title:HIV medicine

    pub_type: 杂志文章

    doi:10.1111/hiv.13018

    authors: Bogorodskaya M,Lyass A,Mahoney TF,Borowsky LH,Sen P,Swirski FK,Srinivasa S,Longenecker CT,Massaro JM,D'Agostino RB Sr,Triant VA

    更新日期:2020-12-08 00:00:00

  • How reliable is an undetectable viral load?

    abstract:OBJECTIVES:An article by the Swiss AIDS Commission states that patients with stably suppressed viraemia [i.e. several successive HIV-1 RNA plasma concentrations (viral loads, VL) below the limits of detection during 6 months or more of highly active antiretroviral therapy (HAART)] are unlikely to be infectious. Questio...

    journal_title:HIV medicine

    pub_type: 杂志文章

    doi:10.1111/j.1468-1293.2009.00714.x

    authors: Combescure C,Vallier N,Ledergerber B,Cavassini M,Furrer H,Rauch A,Battegay M,Bernasconi E,Vernazza P,Hirschel B,Swiss HIV Cohort Study.

    更新日期:2009-09-01 00:00:00

  • The effects of enfuvirtide therapy on body composition and metabolic parameters over 48 weeks in the TORO body imaging substudy.

    abstract:OBJECTIVE:The aim of the study was to compare the metabolic and morphological effects of enfuvirtide plus an optimized background (OB) regimen vs. OB alone (control group) in treatment-experienced patients in the T-20 vs. Optimized Regimen Only (TORO) studies. METHODS:Body composition and metabolic changes were invest...

    journal_title:HIV medicine

    pub_type: 杂志文章,随机对照试验

    doi:10.1111/j.1468-1293.2010.00845.x

    authors: Cooper DA,Cordery DV,Reiss P,Henry K,Nelson M,O'Hearn M,Reynes J,Arastéh K,Chung J,Rowell L,Guimaraes D,Bertasso A,TORO 1 and TORO 2 Study Groups.

    更新日期:2011-01-01 00:00:00

  • Subgroup analysis of virological response rates with once- and twice-daily darunavir/ritonavir in treatment-experienced patients without darunavir resistance-associated mutations in the ODIN trial.

    abstract:BACKGROUND:ODIN (once-daily darunavir in treatment-experienced patients) was a 48-week, phase III, randomized, open-label trial comparing once-daily (qd) darunavir/ritonavir (DRV/r) 800/100 mg with twice-daily (bid) DRV/r 600/100 mg, both with an optimized background regimen [OBR; at least two nucleoside reverse transc...

    journal_title:HIV medicine

    pub_type: 杂志文章,随机对照试验

    doi:10.1111/hiv.12024

    authors: Sension M,Cahn P,Domingo P,Hodder S,Opsomer M,Lathouwers E,Van de Casteele T,Tomaka F

    更新日期:2013-08-01 00:00:00

  • Triple nucleoside reverse transcriptase inhibitor- vs. nonnucleoside reverse transcriptase inhibitor-containing regimens as first-line therapy: efficacy and durability in a prospective cohort of French HIV-infected patients.

    abstract:OBJECTIVE:Based on the short-term results of the AIDS Clinical Trials Group (ACTG) A5095 trial, zidovudine (ZDV)/lamivudine (3TC)/abacavir (ABC) is no longer recommended as a first-line antiretroviral regimen. Data on the efficacy of this triple nucleoside reverse transcriptase inhibitor (NRTI) combination compared wit...

    journal_title:HIV medicine

    pub_type: 杂志文章,多中心研究

    doi:10.1111/j.1468-1293.2005.00315.x

    authors: Cuzin L,Pugliese P,Bugnon F,Delpierre C,Cua E,Billaud E,Massip P,Raffi F,Dellamonica P

    更新日期:2005-11-01 00:00:00

  • Antiviral activity of apricitabine in treatment-experienced HIV-1-infected patients with M184V who are failing combination therapy.

    abstract:OBJECTIVES:Apricitabine (ATC) is a novel deoxycytidine analogue nucleoside reverse transcriptase inhibitor (NRTI) with significant antiviral activity in vitro, including activity against HIV-1 with reverse transcriptase mutations that confer resistance to other NRTIs. ATC has shown promising antiviral activity and good...

    journal_title:HIV medicine

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1111/j.1468-1293.2010.00887.x

    authors: Cahn P,Altclas J,Martins M,Losso M,Cassetti I,Cooper DA,Cox S

    更新日期:2011-07-01 00:00:00

  • Oral candidiasis and seborrheic dermatitis in HIV-infected patients on highly active antiretroviral therapy.

    abstract:BACKGROUND:Mucocutaneous manifestations such as oral candidiasis (OC) and seborrheic dermatitis (SD) are very common HIV-related opportunistic events and are usually initial markers of immunodeficiency. AIM:The purpose of this study was to evaluate the efficacy of highly active antiretroviral therapy (HAART) in the re...

    journal_title:HIV medicine

    pub_type: 临床试验,杂志文章

    doi:10.1111/j.1468-1293.2004.00185.x

    authors: Dunic I,Vesic S,Jevtovic DJ

    更新日期:2004-01-01 00:00:00

  • Cardiovascular disease risk and its determinants in people living with HIV across different settings in South Africa.

    abstract:OBJECTIVES:Socio-economic factors and lifestyle are known to differ across geographies and populations, which may result in distinct risk profiles for cardiovascular disease (CVD). This study assessed carotid intima-media thickness (CIMT), a proxy for CVD, and its determinants in two groups of people living with HIV (P...

    journal_title:HIV medicine

    pub_type: 杂志文章

    doi:10.1111/hiv.12831

    authors: Roozen G,Vos AG,Tempelman HA,Venter W,Grobbee DE,Scheuermaier K,Klipstein-Grobusch K

    更新日期:2020-07-01 00:00:00

  • Role and interpretation of fluorodeoxyglucose-positron emission tomography/computed tomography in HIV-infected patients with fever of unknown origin: a prospective study.

    abstract:OBJECTIVES:The aim of the study was to evaluate prospectively the usefulness of fluorodeoxyglucose-positron emission tomography/computed tomography (FDG-PET/CT) in investigation of fever of unknown origin (FUO) in HIV-positive patients and to determine whether HIV viraemia impacts on FDG-PET/CT performance. METHODS:Th...

    journal_title:HIV medicine

    pub_type: 杂志文章

    doi:10.1111/hiv.12030

    authors: Martin C,Castaigne C,Tondeur M,Flamen P,De Wit S

    更新日期:2013-09-01 00:00:00

  • CD4:CD8 ratio in children with perinatally acquired HIV-1 infection.

    abstract:OBJECTIVES:In adults with horizontally acquired HIV infection, an inverted CD4:CD8 ratio is associated with persistent immune activation, size of HIV reservoir and predicts an increased risk of non-AIDS-defining adverse events. Normalization of this ratio with antiretroviral therapy (ART) is suboptimal in adults, despi...

    journal_title:HIV medicine

    pub_type: 杂志文章

    doi:10.1111/hiv.12642

    authors: Seers T,Vassallo P,Pollock K,Thornhill JP,Fidler S,Foster C

    更新日期:2018-10-01 00:00:00

  • Inhibitory quotient as a prognostic factor of response to a salvage antiretroviral therapy containing ritonavir-boosted saquinavir. The CIVSA Study.

    abstract:BACKGROUND:The addition of a low dose of ritonavir to protease inhibitors (PIs) has become a widespread strategy to improve PI pharmacokinetics. As resistance is a major barrier to long-term suppression, in salvage therapy genotype and/or phenotype scoring is currently used to predict the response. We evaluated the rel...

    journal_title:HIV medicine

    pub_type: 临床试验,杂志文章,多中心研究

    doi:10.1111/j.1468-1293.2007.00464.x

    authors: Mallolas J,Blanco J,Labarga P,Vergara A,Ocampo A,Sarasa M,Arnedo M,López-Púa Y,García J,Juega J,Guelar A,Terrón A,Dalmau D,García I,Zárraga M,Martínez E,Carné X,Pumarola T,Escayola R,Gatell J

    更新日期:2007-05-01 00:00:00

  • End-stage renal disease and dialysis in HIV-positive patients: observations from a long-term cohort study with a follow-up of 22 years.

    abstract:OBJECTIVES:Renal disease is a common and serious complication in HIV-infected patients. METHODS:A retrospective cohort analysis for the period 1989-2010 was carried out to determine the prevalence, incidence and risk factors for end-stage renal disease (ESRD). ESRD was defined as initiation of renal replacement therap...

    journal_title:HIV medicine

    pub_type: 杂志文章

    doi:10.1111/j.1468-1293.2012.01045.x

    authors: Bickel M,Marben W,Betz C,Khaykin P,Stephan C,Gute P,Haberl A,Knecht G,Wolf T,Brodt HR,Geiger H,Herrmann E,Jung O

    更新日期:2013-03-01 00:00:00

  • The durability of virological success of tenofovir and didanosine dosed at either 400 or 250 mg once daily.

    abstract::Tenofovir (TDF) co-administered with didanosine (ddI) 400 mg increases ddI plasma concentrations by up to 60%, raising concerns over toxicity. To limit this interaction, the dosage of ddI may be reduced to 250 mg once daily when co-prescribed with TDF. In this clinical cohort, highly active antiretroviral therapy regi...

    journal_title:HIV medicine

    pub_type: 杂志文章

    doi:10.1111/j.1468-1293.2005.00279.x

    authors: Tung MY,Mandalia S,Bower M,Gazzard B,Nelson M

    更新日期:2005-05-01 00:00:00

  • The case for indicator condition-guided HIV screening.

    abstract::One-half of the estimated 2.5 million people who now live with HIV in the World Health Organization (WHO) European Region are still diagnosed late. A central question is which clinical scenarios should trigger an HIV test recommendation in order to avoid late presentation. Drawing on the work of the HIV Indicator Dise...

    journal_title:HIV medicine

    pub_type: 杂志文章

    doi:10.1111/hiv.12022

    authors: Lazarus JV,Hoekstra M,Raben D,Delpech V,Coenen T,Lundgren JD,HIV in Europe Initiative Steering Committee.

    更新日期:2013-08-01 00:00:00

  • Sweden, the first country to achieve the Joint United Nations Programme on HIV/AIDS (UNAIDS)/World Health Organization (WHO) 90-90-90 continuum of HIV care targets.

    abstract:OBJECTIVES:The Joint United Nations Programme on HIV/AIDS (UNAIDS)/World Health Organization (WHO) 90-90-90 goals propose that 90% of all people living with HIV should know their HIV status, 90% of those diagnosed should receive antiretroviral therapy (ART), and 90% of those should have durable viral suppression. We ha...

    journal_title:HIV medicine

    pub_type: 杂志文章

    doi:10.1111/hiv.12431

    authors: Gisslén M,Svedhem V,Lindborg L,Flamholc L,Norrgren H,Wendahl S,Axelsson M,Sönnerborg A

    更新日期:2017-04-01 00:00:00

  • HIV testing strategies outside of health care settings in the European Union (EU)/European Economic Area (EEA): a systematic review to inform European Centre for Disease Prevention and Control guidance.

    abstract:OBJECTIVES:In recent years, new technologies and new approaches to scale up HIV testing have emerged. The objective of this paper was to synthesize the body of recent evidence on strategies aimed at increasing the uptake and coverage of HIV testing outside of health care settings in the European Union (EU)/European Eco...

    journal_title:HIV medicine

    pub_type: 杂志文章

    doi:10.1111/hiv.12807

    authors: Croxford S,Tavoschi L,Sullivan AK,Combs L,Raben D,Delpech V,Jakobsen SF,Amato-Gauci AJ,Desai S

    更新日期:2020-03-01 00:00:00

  • Diagnosing HIV infection in patients presenting with glandular fever-like illness in primary care: are we missing primary HIV infection?

    abstract:OBJECTIVES:The aim of the study was to examine the prevalence of HIV infection in patients presenting in primary care with glandular fever (GF)-like illness. METHODS:Samples from primary care submitted for a GF screen between April 2009 and June 2010 were identified. Samples without an HIV request were anonymized and ...

    journal_title:HIV medicine

    pub_type: 杂志文章

    doi:10.1111/j.1468-1293.2012.01023.x

    authors: Hsu DT,Ruf M,O'Shea S,Costelloe S,Peck J,Tong CY

    更新日期:2013-01-01 00:00:00

  • Lopinavir and atazanavir in pregnancy: comparable infant outcomes, virological efficacies and preterm delivery rates.

    abstract:OBJECTIVES:The aim of the study was to identify differences in infant outcomes, virological efficacy, and preterm delivery (PTD) outcome between women exposed to lopinavir/ritonavir (LPV/r) and those exposed to atazanavir/ritonavir (ATV/r). METHODS:A retrospective case note review was carried out. The case notes of 49...

    journal_title:HIV medicine

    pub_type: 杂志文章

    doi:10.1111/hiv.12277

    authors: Perry ME,Taylor GP,Sabin CA,Conway K,Flanagan S,Dwyer E,Stevenson J,Mulka L,McKendry A,Williams E,Barbour A,Dermont S,Roedling S,Shah R,Anderson J,Rodgers M,Wood C,Sarner L,Hay P,Hawkins D,deRuiter A

    更新日期:2016-01-01 00:00:00

  • Successful switch to rilpivirine/tenofovir/emtricitabine in HIV-1-infected patients with an isolated K103N mutation acquired during prior nonnucleoside reverse transcriptase inhibitor therapy.

    abstract:OBJECTIVES:Whether treatment-experienced HIV-1-infected patients with an acquired K103N mutation after failing nonnucleoside reverse transcriptase inhibitor (NNRTI) regimens can be treated with rilpivirine is unknown. The aim of this pilot study was to evaluate the efficacy of rilpivirine/tenofovir/emtricitabine in HIV...

    journal_title:HIV medicine

    pub_type: 杂志文章

    doi:10.1111/hiv.12157

    authors: Rokx C,Verbon A,Rijnders BJ

    更新日期:2014-11-01 00:00:00